Difference between revisions of "IgG4-related systemic diseases"

From Libre Pathology
Jump to navigation Jump to search
Line 19: Line 19:
*† Minimum number dependent on anatomical site.<ref name=pmid28701054/>
*† Minimum number dependent on anatomical site.<ref name=pmid28701054/>
** Lymph node: 100 (or 50) plasma cells/HPF, where 1 HPF ~ 0.196 mm*mm and 3 HPFs are assessed.<ref>{{cite journal |authors=Cheuk W, Chan JK |title=Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity |journal=Semin Diagn Pathol |volume=29 |issue=4 |pages=226–34 |date=November 2012 |pmid=23068302 |doi=10.1053/j.semdp.2012.07.001 |url=}}</ref>
** Lymph node: 100 (or 50) plasma cells/HPF, where 1 HPF ~ 0.196 mm*mm and 3 HPFs are assessed.<ref>{{cite journal |authors=Cheuk W, Chan JK |title=Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity |journal=Semin Diagn Pathol |volume=29 |issue=4 |pages=226–34 |date=November 2012 |pmid=23068302 |doi=10.1053/j.semdp.2012.07.001 |url=}}</ref>
==See also==
*[[HPFitis]].


==References==
==References==

Revision as of 14:41, 3 March 2022

The IgG4-related systemic diseases, also IgG4-related diseases, are diseases characterized IgG4 positive plasma cells and fibrosis.[1]

List of IgG4-related diseases

Microscopic

Features:[5]

  • At least 10 IgG4 +ve plasma cells.†
  • >40% of plasma cells IgG4 +ve.

Note:

  • † Minimum number dependent on anatomical site.[5]
    • Lymph node: 100 (or 50) plasma cells/HPF, where 1 HPF ~ 0.196 mm*mm and 3 HPFs are assessed.[6]

See also

References

  1. Khosroshahi, A.; Stone, JH. (Jan 2011). "A clinical overview of IgG4-related systemic disease.". Curr Opin Rheumatol 23 (1): 57-66. doi:10.1097/BOR.0b013e3283418057. PMID 21124086.
  2. 2.0 2.1 2.2 Kamisawa, T.; Okamoto, A. (Jul 2008). "IgG4-related sclerosing disease.". World J Gastroenterol 14 (25): 3948-55. PMID 18609677.
  3. Saab, ST.; Hornick, JL.; Fletcher, CD.; Olson, SJ.; Coffin, CM. (Apr 2011). "IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?". Mod Pathol 24 (4): 606-12. doi:10.1038/modpathol.2010.226. PMID 21297584.
  4. Barnabas, A.; Chapman, RW. (Feb 2012). "Primary sclerosing cholangitis: is any treatment worthwhile?". Curr Gastroenterol Rep 14 (1): 17-24. doi:10.1007/s11894-011-0230-8. PMID 22124849.
  5. 5.0 5.1 Abraham M, Khosroshahi A (September 2017). "Diagnostic and treatment workup for IgG4-related disease". Expert Rev Clin Immunol 13 (9): 867–875. doi:10.1080/1744666X.2017.1354698. PMC 5896560. PMID 28701054. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896560/.
  6. Cheuk W, Chan JK (November 2012). "Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity". Semin Diagn Pathol 29 (4): 226–34. doi:10.1053/j.semdp.2012.07.001. PMID 23068302.